Anvisa has rejected the import of the Russian Covid-19 vaccine, Sputnik V stating that it lacks consistent and reliable data. The coronavirus vaccine was requested by state Governors to fight against the second Covid-19 wave that hit the country.
The vaccine was developed by the Gamaleya National Center of Epidemiology and Microbiology it is based on a human adenoviral vectors platform. The Brazilian National Health Surveillance Agency Anvisa has a five-strong board who voted unanimously against the Russian vaccine. It has approval as technical staff had emphasised ‘inherent risks’ and ‘serious’ defects, pointing out the lack of data ensuring the safety, quality and effectiveness of the shot.
Last month, the European Medicines Agency’s Committee for Medicinal Products for Human Use initiated a rolling review of the Russian Covid-19 vaccine, Sputnik V. Russia’s coronavirus vaccine is approved in many countries across the globe.
Recently, the Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund reported that the vaccine showed a 97.6% efficacy against Covid-19. The infection rate of 0.027% starting from the 35th day on administering the first dose. These results are from a real-world assessment based on data from 3.8 million people who received the two shots of the vaccine.Since the pandemic onset, 14.4 million confirmed Covid-19 cases and around 400,000 deaths were reported in Brazil. Estimates from the health ministry data show that 13% of the country’s population have received the first dose.